Q-omics provides the consensus-scored MIR548P profile across patient tissues and cancer cell-line models. MIR548P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MIR548P is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MIR548P RNA expression shows 6,749 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight ESCA, KIRC, and COAD as cancer lineages where MIR548P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548P survival associations across molecular data types. MIR548P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548P RNA expression–survival associations across cancer types. High MIR548P expression shows unfavorable associations in THCA, GBM, LUSC and SKCM, but favorable associations in ESCA and PAAD. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for MIR548P RNA expression.
This table summarizes MIR548P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548P shows lower tumor expression in COAD and LUSC and higher tumor expression in KIRC. The KIRC box plot shows higher MIR548P RNA expression in tumor versus normal tissue (log2 FC = +0.408, t-test p < 0.001).
This table shows molecular features associated with MIR548P in patient tissues and cancer cell lines. In patient samples, MIR548P shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
